NDTDI is a tricyclic tryptamine derivative which is thought to act as a serotonin receptor agonist, though its pharmacology has not been studied in detail. It is a structurally simplified analogue of LSD and is reported to retain similar effects, though with many times lower potency. It has been sold as a designer drug since 2016 and was first identified by a forensic laboratory in Slovenia in 2017.
Property | Value |
---|---|
dbo:abstract |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:c |
|
dbp:h |
|
dbp:iupacName |
|
dbp:legalStatus |
|
dbp:n |
|
dbp:o |
|
dbp:smiles |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |